Skip to main content

Articles

Immunotherapy, Oncology
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
Phoebe Starr
Read More
Immunotherapy, Oncology
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
Read More
Practice Management
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Read More
Leukemia, Oncology
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Read More
Lymphoma
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
Read More
FDA Approvals
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
Read More
Practice Management
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer
Chase Doyle
Read More
FDA Approvals, In the News
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Read More
Pulmonary
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
Kenneth LaPensee, PhD; Rohit Mistry, MPharm, MBA, MSc; Thomas Lodise, PharmD, PhD
Read More
Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
Kenneth LaPensee, PhD; Rohit Mistry, MPharm, MBA, MSc; Thomas Lodise, PharmD, PhD
Read More
Page 59 of 244
Results 581 - 590 of 2434